Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 512 GBX 0.13% Market Closed
Market Cap: 3.4B GBX

ROCE
Return on Capital Employed

18.2%
Current
17%
Average
2.2%
Industry

ROCE, or Return on Capital Employed, is a financial ratio that measures a company’s profitability in relation to the capital it employs.

ROCE
18.2%
=
EBIT
602m
/
Capital Employed
3.3B

ROCE Across Competitors

No Stocks Found

Hikma Pharmaceuticals PLC
Glance View

Hikma Pharmaceuticals PLC, a Jordanian-British multinational, began its journey in the heart of Amman, Jordan, in 1978, founded by Samih Darwazah. Over the years, it has evolved from a local pharmaceutical manufacturer into a global powerhouse, recognized as a key player in the generic pharmaceutical industry. The company's core strategy revolves around the production and distribution of a wide array of generic medications, serving diverse therapeutic categories such as cardiovascular, oncology, and infectious diseases. Hikma's competitive edge lies in its ability to produce high-quality and cost-effective medicines, which are crucial in both high-demand regions and emerging markets where affordable healthcare options are often limited. By leveraging its robust manufacturing capabilities and regulatory expertise, Hikma efficiently supplies generic and branded medications to over 50 countries worldwide, nurturing its growth and bolstering its market position. Driving the gears of Hikma's revenue machine are its three main operational segments: Injectables, Generics, and Branded pharmaceuticals. The Injectables division, a significant contributor to its financial health, supplies hospitals with critical sterile products, benefiting especially when acute care needs surge. Meanwhile, the Generics division continues to expand its footprint in the U.S. market, offering cost-effective alternatives to brand-name drugs, riding the wave of patent expirations. The Branded segment, deeply rooted in the Middle East and North Africa, capitalizes on Hikma's regional expertise and trusted brand reputation. Through this diversified business model, Hikma not only fortifies its financial stability but also ensures resilience against market fluctuations, steering the firm towards sustainable growth amidst an ever-evolving global pharmaceutical landscape.

HIK Intrinsic Value
HIDDEN
Show
What is Return on Capital Employed?

ROCE, or Return on Capital Employed, is a financial ratio that measures a company’s profitability in relation to the capital it employs.

ROCE
18.2%
=
EBIT
602m
/
Capital Employed
3.3B
What is the ROCE of Hikma Pharmaceuticals PLC?

Based on Hikma Pharmaceuticals PLC's most recent financial statements, the company has ROCE of 18.2%.

Back to Top